Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $61

Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $67 to $61.